<DOC>
	<DOCNO>NCT01848002</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety pharmacokinetics multiple dos catridecacog ( recombinant factor XIII , rFXIII ) healthy volunteer .</brief_summary>
	<brief_title>Safety Pharmacokinetics Recombinant Factor XIII Administration Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Normal platelet count clot parameter Adequate renal hepatic function Negative serum pregnancy test within 21 day prior enrollment negative urine pregnancy test admission clinical research unit ( subject female childbearing potential ) Agreement use medically accept form contraception time enrollment completion followup study visit ( subject sexually active male female childbearing potential ) Negative drug negative alcohol screen Known antibody hypersensitivity FXIII Known bleed hematologic disorder Known allergy yeast Receipt blood product within 30 day screen Donation blood within 30 day prior enrollment Surgical procedure type within 30 day prior enrollment History autoimmune disorder involve autoantibody , e.g. , systemic lupus erythematosus Treatment experimental agent within 30 day study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>